8-K Announcements
6Material company update
Mar 27, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Mar 24, 2026·SEC
Harrow Health, Inc.(HROW)Earnings, Financials & Key Ratios
HROW•NASDAQ
$40.27
$1.5B mkt cap·Price updated May 6, 2026
AboutHarrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.Show more
- Revenue$272M+36.4%
- EBITDA-$9M-140.7%
- Net Income-$5M+70.6%
- EPS (Diluted)-0.14+71.4%
- Gross Margin75.05%-0.4%
- EBITDA Margin-3.27%-129.9%
- Operating Margin11.21%+153.6%
- Net Margin-1.89%+78.5%
- ROE-8.47%+66.3%
- ROIC9.5%+213.8%
- Debt/Equity4.84+46.5%
HROW Key Insights
Harrow Health, Inc. (HROW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 41.0%
✗Weaknesses
- ✗High debt to equity ratio of 4.8x
- ✗Expensive at 28.4x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
HROW Price & Volume
Harrow Health, Inc. (HROW) stock price & volume — 10-year historical chart
Loading chart...
HROW Growth Metrics
Harrow Health, Inc. (HROW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years39.56%
5 Years40.99%
3 Years45.39%
TTM36.41%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM70.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM66.57%
Return on Capital
10 Years-20.19%
5 Years3.52%
3 Years4.51%
Last Year10.16%
HROW Recent Earnings
Harrow Health, Inc. (HROW) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (17%)
Q2 2026Latest
Mar 2, 2026EPS
$0.26
Est $0.40
-35.0%
Revenue
$89M
Est $90M
-1.0%
Q4 2025
Nov 10, 2025EPS
$0.33
Est $0.22
+50.0%
Revenue
$72M
Est $88M
-18.6%
Q3 2025
Aug 11, 2025EPS
$0.24
Est $0.31
-23.4%
Revenue
$64M
Est $74M
-13.8%
Q2 2025
May 8, 2025EPS
$0.38
Est $0.02
-2000.0%
Revenue
$48M
Est $68M
-29.5%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.26vs $0.40-35.0% | $89Mvs $90M-1.0% |
| Q4 2025 | Nov 10, 2025 | $0.33vs $0.22+50.0% | $72Mvs $88M-18.6% |
| Q3 2025 | Aug 11, 2025 | $0.24vs $0.31-23.4% | $64Mvs $74M-13.8% |
| Q2 2025 | May 8, 2025 | $0.38vs $0.02-2000.0% | $48Mvs $68M-29.5% |
Based on last 12 quarters of dataView full earnings history →
HROW Peer Comparison
Harrow Health, Inc. (HROW) competitors in Specialty pharma brand consolidators — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PAHC | 2.38B | 58.64 | 49.28 | 27.37% | 6.29% | 30.81% | 2.67 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 SGHT | 232.23M | 4.30 | -5.81 | -3.13% | -46.83% | -59.1% | 0.64 | |
 ICUI | 2.95B | 119.59 | 3986.33 | -6.33% | -0.32% | -0.35% | 0.60 | |
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 PRGO | 1.69B | 12.26 | -1.19 | -2.75% | -43.5% | -50.65% | 1.35 |
Compare HROW vs Peers
Harrow Health, Inc. (HROW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
HROW Income Statement
Harrow Health, Inc. (HROW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 26.77M | 41.37M | 51.16M | 48.87M | 72.48M | 88.59M | 130.19M | 199.61M | 272.3M |
| Revenue Growth % | 34.26% | 54.52% | 23.67% | -4.48% | 48.3% | 22.24% | 46.95% | 53.32% | 36.41% |
| Cost of Goods Sold | 13.51M | 16.52M | 16.75M | 14.46M | 18.21M | 25.38M | 39.64M | 49.24M | 67.93M |
| COGS % of Revenue | 50.44% | 39.93% | 32.74% | 29.59% | 25.13% | 28.65% | 30.45% | 24.67% | 24.95% |
| Gross Profit | 13.27M▲ 0% | 24.85M▲ 87.3% | 34.42M▲ 38.5% | 34.41M▼ 0.0% | 54.26M▲ 57.7% | 63.21M▲ 16.5% | 90.55M▲ 43.3% | 150.37M▲ 66.1% | 204.37M▲ 35.9% |
| Gross Margin % | 49.56% | 60.07% | 67.26% | 70.41% | 74.87% | 71.35% | 69.55% | 75.33% | 75.05% |
| Gross Profit Growth % | 31.23% | 87.29% | 38.49% | -0.02% | 57.7% | 16.49% | 43.25% | 66.06% | 35.91% |
| Operating Expenses | 25.43M | 30.07M | 39.21M | 34.02M | 52.65M | 61.29M | 90.12M | 141.55M | 173.85M |
| OpEx % of Revenue | 94.99% | 72.68% | 76.64% | 69.62% | 72.64% | 69.18% | 69.22% | 70.91% | 63.85% |
| Selling, General & Admin | 25.02M | 29.24M | 33.1M | 0 | 39.81M | 0 | 0 | 0 | 152.91M |
| SG&A % of Revenue | 93.45% | 70.68% | 64.68% | - | 54.94% | - | - | - | 56.16% |
| Research & Development | 413K | 825K | 2.08M | 2.41M | 11.08M | 3.05M | 6.65M | 12.23M | 20.94M |
| R&D % of Revenue | 1.54% | 1.99% | 4.07% | 4.94% | 15.29% | 3.44% | 5.11% | 6.13% | 7.69% |
| Other Operating Expenses | 0 | 103K | 4.03M | 31.61M | 1.75M | 58.24M | 83.47M | 129.32M | 0 |
| Operating Income | -12.16M▲ 0% | -5.22M▲ 57.1% | -4.79M▲ 8.1% | 385K▲ 108.0% | 1.61M▲ 319.2% | 1.92M▲ 18.9% | 431K▼ 77.5% | 8.82M▲ 1946.9% | 30.52M▲ 245.9% |
| Operating Margin % | -45.43% | -12.61% | -9.37% | 0.79% | 2.23% | 2.17% | 0.33% | 4.42% | 11.21% |
| Operating Income Growth % | 23.42% | 57.11% | 8.09% | 108.03% | 319.22% | 18.9% | -77.54% | 1946.87% | 245.9% |
| EBITDA | -10.4M | -3.37M | -2.13M | 2.25M | 3.35M | 4.75M | 11.57M | 21.87M | -8.91M |
| EBITDA Margin % | -38.84% | -8.16% | -4.17% | 4.61% | 4.63% | 5.36% | 8.89% | 10.96% | -3.27% |
| EBITDA Growth % | 28.17% | 67.55% | 36.81% | 205.72% | 48.85% | 41.58% | 143.54% | 89.09% | -140.73% |
| D&A (Non-Cash Add-back) | 1.76M | 1.84M | 2.66M | 1.87M | 1.74M | 2.83M | 11.14M | 13.05M | 0 |
| EBIT | -12.16M | -5.22M | -706K | 748K | 3.36M | 1.92M | 811K | 9.07M | -8.91M |
| Net Interest Income | -3.03M | -2.73M | -2.5M | -2.24M | -5.44M | -7.24M | -21.32M | -22.79M | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 3.03M | 2.73M | 2.5M | 2.24M | 5.44M | 7.24M | 21.32M | 22.79M | 0 |
| Other Income/Expense | -757K | 19.84M | 0 | -3.8M | -19.49M | -15.93M | -24.14M | -26.14M | -39.42M |
| Pretax Income | -12.92M▲ 0% | 14.63M▲ 213.2% | -117K▼ 100.8% | -3.42M▼ 2818.8% | -17.87M▼ 423.4% | -14.01M▲ 21.6% | -23.71M▼ 69.2% | -17.32M▲ 27.0% | -8.91M▲ 48.6% |
| Pretax Margin % | -48.26% | 35.35% | -0.23% | -6.99% | -24.66% | -15.81% | -18.21% | -8.68% | -3.27% |
| Income Tax | -935K | 0 | 8K | 4K | 133K | 75K | 701K | 161K | -3.77M |
| Effective Tax Rate % | 7.24% | 0% | -6.84% | -0.12% | -0.74% | -0.54% | -2.96% | -0.93% | 42.32% |
| Net Income | -11.98M▲ 0% | 14.63M▲ 222.0% | 168K▼ 98.9% | -3.36M▼ 2098.2% | -18.01M▼ 436.4% | -14.09M▲ 21.8% | -24.41M▼ 73.3% | -17.48M▲ 28.4% | -5.14M▲ 70.6% |
| Net Margin % | -44.76% | 35.35% | 0.33% | -6.87% | -24.85% | -15.9% | -18.75% | -8.76% | -1.89% |
| Net Income Growth % | 37.21% | 222.03% | -98.85% | -2098.21% | -436.4% | 21.77% | -73.3% | 28.39% | 70.6% |
| Net Income (Continuing) | -11.98M | 14.63M | -125K | -3.42M | -18.01M | -14.09M | -24.41M | -17.48M | -5.14M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | -293K | -355K | -355K | -355K | -355K | -355K | -355K |
| EPS (Diluted) | -0.60▲ 0% | 0.61▲ 201.7% | 0.01▼ 98.4% | -0.13▼ 1400.0% | -0.69▼ 430.8% | -0.51▲ 26.1% | -0.75▼ 47.1% | -0.49▲ 34.7% | -0.14▲ 71.4% |
| EPS Growth % | 60% | 201.67% | -98.36% | -1400% | -430.77% | 26.09% | -47.06% | 34.67% | 71.43% |
| EPS (Basic) | -0.60 | 0.67 | 0.01 | -0.13 | -0.69 | -0.51 | -0.75 | -0.49 | -0.14 |
| Diluted Shares Outstanding | 20.03M | 23.81M | 26.47M | 25.89M | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
| Basic Shares Outstanding | 19.98M | 21.92M | 25.32M | 25.89M | 26.76M | 27.46M | 32.62M | 35.65M | 36.76M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
HROW Balance Sheet
Harrow Health, Inc. (HROW) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 8.81M | 32.84M | 36.77M | 40.98M | 60.66M | 118.26M | 139.07M | 189.65M | 211.75M |
| Cash & Short-Term Investments | 4.02M | 28.06M | 29.95M | 32.75M | 50.67M | 101.86M | 82.77M | 47.25M | 72.93M |
| Cash Only | 4.02M | 6.64M | 4.75M | 4.1M | 42.17M | 96.27M | 74.08M | 47.25M | 72.93M |
| Short-Term Investments | 0 | 21.42M | 25.2M | 28.64M | 8.5M | 5.59M | 8.68M | 0 | 0 |
| Accounts Receivable | 1.62M | 1.96M | 2.01M | 2.66M | 4.52M | 6.39M | 36.49M | 116.6M | 110.89M |
| Days Sales Outstanding | 22.14 | 17.33 | 14.33 | 19.88 | 22.75 | 26.32 | 102.3 | 213.21 | 148.65 |
| Inventory | 2.25M | 1.83M | 3.3M | 3.96M | 4.22M | 6.54M | 10.87M | 10.7M | 13.52M |
| Days Inventory Outstanding | 60.78 | 40.52 | 71.94 | 99.99 | 84.51 | 94.06 | 100.06 | 79.32 | 72.66 |
| Other Current Assets | 124K | 125K | 922K | 1.05M | 92K | 118K | 1.75M | 3.41M | 14.4M |
| Total Non-Current Assets | 15.11M | 16.61M | 22.32M | 16.49M | 37.67M | 39.12M | 172.68M | 199.32M | 187.73M |
| Property, Plant & Equipment | 6.21M | 6.38M | 11.93M | 10.67M | 9.08M | 11M | 12.44M | 12.29M | 11.04M |
| Fixed Asset Turnover | 4.31x | 6.49x | 4.29x | 4.58x | 7.99x | 8.05x | 10.46x | 16.24x | 24.66x |
| Goodwill | 2.23M | 2.23M | 332K | 332K | 332K | 332K | 332K | 332K | 332K |
| Intangible Assets | 2.86M | 3.06M | 2.34M | 2.52M | 17.13M | 25.84M | 159.91M | 186.7M | 175.17M |
| Long-Term Investments | 3.51M | 4.95M | 7.71M | 2.97M | 11.13M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 302K | 4.95M | 7.71M | 0 | 12.45M | 1.95M | 0 | 0 | 1.18M |
| Total Assets | 23.92M▲ 0% | 49.45M▲ 106.8% | 59.09M▲ 19.5% | 57.47M▼ 2.7% | 98.33M▲ 71.1% | 157.38M▲ 60.1% | 311.75M▲ 98.1% | 388.97M▲ 24.8% | 399.48M▲ 2.7% |
| Asset Turnover | 1.12x | 0.84x | 0.87x | 0.85x | 0.74x | 0.56x | 0.42x | 0.51x | 0.68x |
| Asset Growth % | -12.22% | 106.76% | 19.48% | -2.73% | 71.08% | 60.05% | 98.09% | 24.77% | 2.7% |
| Total Current Liabilities | 5.77M | 11.9M | 12.28M | 10.8M | 9.72M | 18.63M | 49.34M | 91.34M | 96.3M |
| Accounts Payable | 3.88M | 4.97M | 7.41M | 3.65M | 5.17M | 6.44M | 21.42M | 38.76M | 35.35M |
| Days Payables Outstanding | 105 | 109.71 | 161.46 | 91.99 | 103.68 | 92.61 | 197.27 | 287.3 | 189.96 |
| Short-Term Debt | 598K | 3.25M | 1.77M | 3.9M | 0 | 0 | 806K | 0 | 887K |
| Deferred Revenue (Current) | 29K | 119K | 57K | 0 | 16K | 113K | 0 | 44K | 788K |
| Other Current Liabilities | -545K | 564K | 293K | 66K | 1.16M | 0 | 21.66M | 0 | 59.27M |
| Current Ratio | 1.53x | 2.76x | 2.99x | 3.79x | 6.24x | 6.35x | 2.82x | 2.08x | 2.20x |
| Quick Ratio | 1.14x | 2.61x | 2.72x | 3.43x | 5.81x | 6.00x | 2.60x | 1.96x | 2.06x |
| Cash Conversion Cycle | -22.08 | -51.87 | -75.19 | 27.88 | 3.58 | 27.77 | 5.09 | 5.23 | 31.35 |
| Total Non-Current Liabilities | 15.53M | 12.8M | 19.38M | 19.85M | 77.68M | 111.51M | 192.41M | 228.33M | 251.09M |
| Long-Term Debt | 14.01M | 12M | 12.22M | 12.38M | 71.65M | 104.17M | 183.17M | 219.54M | 251.09M |
| Capital Lease Obligations | 720K | 0 | 6.36M | 6.67M | 6.02M | 7.33M | 6.52M | 8.79M | 7.91M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 800K | 800K | 800K | 800K | 0 | 0 | 2.71M | 0 | 0 |
| Total Liabilities | 21.3M | 24.7M | 31.67M | 30.65M | 87.4M | 130.14M | 241.75M | 319.67M | 347.39M |
| Total Debt | 15.33M | 15.25M | 20.99M | 23.53M | 77.96M | 112.23M | 190.5M | 228.83M | 251.98M |
| Net Debt | 11.31M | 8.61M | 16.24M | 19.43M | 35.79M | 15.96M | 116.42M | 181.58M | 179.05M |
| Debt / Equity | 5.86x | 0.62x | 0.77x | 0.88x | 7.13x | 4.12x | 2.72x | 3.30x | 4.84x |
| Debt / EBITDA | - | - | - | 10.44x | 23.24x | 23.63x | 16.47x | 10.46x | - |
| Net Debt / EBITDA | - | - | - | 8.62x | 10.67x | 3.36x | 10.06x | 8.30x | - |
| Interest Coverage | -4.02x | -1.91x | -1.92x | 0.17x | 0.30x | 0.26x | 0.02x | 0.39x | - |
| Total Equity | 2.62M▲ 0% | 24.75M▲ 846.5% | 27.42M▲ 10.8% | 26.83M▼ 2.2% | 10.93M▼ 59.3% | 27.24M▲ 149.2% | 70M▲ 157.0% | 69.3M▼ 1.0% | 52.09M▼ 24.8% |
| Equity Growth % | -59.34% | 846.5% | 10.78% | -2.15% | -59.26% | 149.2% | 156.98% | -1.01% | -24.83% |
| Book Value per Share | 0.13 | 1.04 | 1.04 | 1.04 | 0.41 | 0.99 | 2.15 | 1.94 | 1.42 |
| Total Shareholders' Equity | 2.62M | 24.75M | 27.71M | 27.18M | 11.29M | 27.59M | 70.36M | 69.65M | 52.45M |
| Common Stock | 21K | 24K | 26K | 26K | 27K | 30K | 35K | 35K | 37K |
| Retained Earnings | -88.84M | -74.21M | -74.04M | -77.4M | -95.41M | -109.49M | -133.9M | -151.38M | -156.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2.76M | -4.36M | 0 | 0 | 0 | 0 | -409K | 0 | 0 |
| Minority Interest | 0 | 0 | -293K | -355K | -355K | -355K | -355K | -355K | -355K |
HROW Cash Flow Statement
Harrow Health, Inc. (HROW) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.8M | 687K | 950K | -1.1M | 5.08M | 1.71M | 3.84M | -22.2M | 0 |
| Operating CF Margin % | -32.88% | 1.66% | 1.86% | -2.25% | 7.01% | 1.92% | 2.95% | -11.12% | - |
| Operating CF Growth % | 21.51% | 107.8% | 38.28% | -215.79% | 562% | -66.45% | 125.22% | -678.18% | 100% |
| Net Income | -11.98M | 14.63M | -125K | -3.42M | -18.01M | -14.09M | -24.41M | -17.48M | 0 |
| Depreciation & Amortization | 1.76M | 1.84M | 2.66M | 2.74M | 2.4M | 3.67M | 12.34M | 14.54M | 0 |
| Stock-Based Compensation | 2.94M | 2.64M | 2.02M | 2.77M | 5.75M | 7.97M | 15.7M | 17.62M | 0 |
| Deferred Taxes | -935K | -22.47M | -2.4M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -1.29M | 613K | 512K | 3.07M | 15.2M | 9.72M | 7.35M | 7.75M | 0 |
| Working Capital Changes | 700K | 3.44M | -1.72M | -6.27M | -253K | -5.57M | -7.13M | -44.63M | 0 |
| Change in Receivables | 1.39M | -384K | -95K | -866K | -1.83M | -1.86M | -30.34M | -80.23M | 0 |
| Change in Inventory | -821K | 415K | -2.27M | -661K | -255K | -2.32M | -4.33M | 165K | 0 |
| Change in Payables | 346K | 2.37M | 1.34M | -4.66M | 1.73M | 933K | 31.8M | 37.5M | 0 |
| Cash from Investing | -961K | -2.2M | -1.83M | -981K | -18.69M | -1.74M | -152.55M | -33.16M | -5.46M |
| Capital Expenditures | -1.07M | -2.2M | -1.84M | -862K | -1.79M | -2.6M | -1.46M | -1.59M | 0 |
| CapEx % of Revenue | 4.01% | 5.32% | 3.59% | 1.76% | 2.46% | 2.93% | 1.12% | 0.8% | - |
| Acquisitions | 113K | 0 | 4K | 0 | 9.83M | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 113K | 4K | 0 | -119K | -36.55M | 854K | -151.09M | -37.08M | -5.46M |
| Cash from Financing | 4.93M | 4.13M | -1.01M | 1.43M | 51.47M | 54.14M | 126.53M | 28.53M | -12.72M |
| Debt Issued (Net) | 893K | -691K | -1.49M | 2.96M | 71.07M | 31.72M | 74.64M | 29.78M | 0 |
| Equity Issued (Net) | 1000K | 642K | 769K | 0 | -345K | 1000K | 1000K | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | -127K | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -27K | 4.18M | -282K | -1.53M | -19.12M | -234K | -12.63M | -1.25M | -12.72M |
| Net Change in Cash | -4.83M▲ 0% | 2.62M▲ 154.2% | -1.89M▼ 172.1% | -648K▲ 65.7% | 37.87M▲ 5943.5% | 54.1M▲ 42.9% | -22.18M▼ 141.0% | -26.84M▼ 21.0% | 25.68M▲ 195.7% |
| Free Cash Flow | -9.88M▲ 0% | -1.52M▲ 84.7% | -887K▲ 41.5% | -2.09M▼ 136.1% | -23.43M▼ 1018.9% | -6.07M▲ 74.1% | -148.71M▼ 2350.8% | -60.88M▲ 59.1% | 0▲ 100.0% |
| FCF Margin % | -36.89% | -3.66% | -1.73% | -4.28% | -32.33% | -6.85% | -114.22% | -30.5% | - |
| FCF Growth % | 46.19% | 84.65% | 41.49% | -136.08% | -1018.91% | 74.1% | -2350.77% | 59.06% | 100% |
| FCF per Share | -0.49 | -0.06 | -0.03 | -0.08 | -0.88 | -0.22 | -4.56 | -1.71 | - |
| FCF Conversion (FCF/Net Income) | 0.73x | 0.05x | 5.65x | 0.33x | -0.28x | -0.12x | -0.16x | 1.27x | - |
| Interest Paid | 1.54M | 2.1M | 1.97M | 1.79M | 4.82M | 6.48M | 18.89M | 20.59M | 0 |
| Taxes Paid | 9K | 4K | 17K | 4K | 11K | 75K | 0 | 374K | 0 |
HROW Key Ratios
Harrow Health, Inc. (HROW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -756.37% | -264.95% | 106.88% | 0.64% | -12.38% | -95.38% | -73.8% | -50.21% | -25.1% | -8.47% |
| Return on Invested Capital (ROIC) | -153.17% | -72.44% | -16.55% | -9.34% | 0.64% | 2.6% | 3.2% | 0.28% | 3.03% | 9.5% |
| Gross Margin | 50.7% | 49.56% | 60.07% | 67.26% | 70.41% | 74.87% | 71.35% | 69.55% | 75.33% | 75.05% |
| Net Margin | -95.71% | -44.76% | 35.35% | 0.33% | -6.87% | -24.85% | -15.9% | -18.75% | -8.76% | -1.89% |
| Debt / Equity | 2.13x | 5.86x | 0.62x | 0.77x | 0.88x | 7.13x | 4.12x | 2.72x | 3.30x | 4.84x |
| Interest Coverage | -5.70x | -4.02x | -1.91x | -1.92x | 0.17x | 0.30x | 0.26x | 0.02x | 0.39x | - |
| FCF Conversion | 0.59x | 0.73x | 0.05x | 5.65x | 0.33x | -0.28x | -0.12x | -0.16x | 1.27x | - |
| Revenue Growth | 105.25% | 34.26% | 54.52% | 23.67% | -4.48% | 48.3% | 22.24% | 46.95% | 53.32% | 36.41% |
HROW SEC Filings & Documents
Harrow Health, Inc. (HROW) SEC filings — annual & quarterly reports (10-K, 10-Q)
HROW Frequently Asked Questions
Harrow Health, Inc. (HROW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Harrow Health, Inc. (HROW) reported $272.3M in revenue for fiscal year 2025.
Harrow Health, Inc. (HROW) grew revenue by 36.4% over the past year. This is strong growth.
Harrow Health, Inc. (HROW) reported a net loss of $5.1M for fiscal year 2025.
Dividend & Returns
Harrow Health, Inc. (HROW) has a return on equity (ROE) of -8.5%. Negative ROE indicates the company is unprofitable.
Harrow Health, Inc. (HROW) generated $72.8M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More HROW
Harrow Health, Inc. (HROW) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates